Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 1999

View Archived Issues

OraVax, Peptide Therapeutics and Pasteur Merieux Connaught announce agreements

Novel class of PAF antagonists presented by Searle

Phthalimide derivatives from JT selectively inhibit IL-5 and IgE production

Improved treatments for NIDDM in development at Dr. Reddy's and Reddy-Cheminor

Inhibitors of cGMP phosphodiesterases discovered at Bayer

Selective COX-2 inhibitors evaluated for antiinflammatory and analgesic effects at Grelan

Daiichi patents broad-spectrum antibacterial series

Otsuka discovers new platelet aggregation inhibitors and antithrombotic agents

Grant will help Copernicus develop novel targeted CF gene therapy

Neurobiological Technologies awarded SBIR grant for Xerecept development

Gensia Sicor establishes marketing agreement with Abbott

BioFocus and Pharmacia & Upjohn join forces in drug discovery

Phase III trial for angina treatment begins at international sites

Increased PKC activity activity and role for PKC-beta inhibitors in heart failure

FDA advisory committee recommends approval of Natrecor

Genentech and Schwarz enter collaboration for GH products

New herpes vaccine from Cel-Sci proves effective in protecting mice

CPMP recommends approval of Paxene for AIDS-related KS

First market introduction for new asthma treatment --Seretide Diskus

Genetix and Cordis to develop angiogenic gene therapy products for cardiovascular disease

Regulatory plans for gatifloxacin outlined by Kyorin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...